Roth Capital analyst Scott Henry maintained a Neutral rating on Alexza Pharmaceuticals (NASDAQ:ALXA), and reduced his price target to $2.50 (from $5.
In a research report published August 8, Roth Capital analyst Scott Henry downgraded shares of Alexza Pharmaceuticals (ALXA) from a Buy to a Neutral rating with …
